Pulmatrix, Inc.
PULMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the. At a $6.2M market cap, Pulmatrix, Inc. ranks as a micro-cap company within healthcare. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Market Cap
$6.2M
Beta
1.90
P/E (TTM)
—
P/E (Fwd)
-0.38
EPS (TTM)
$-1.24
EPS (Fwd)
$-4.50
ROE
-84.3%
ROA
-46.0%
Cash
$3.3M
Total Debt
$0
Free CF
-$3.7M
52W Change
-72.0%
Annual Financials
Cash vs Debt
Where PULM stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, PULM finished 20.20% below its 150-day moving average ($2.03) and 40.00% below its 200-day moving average ($2.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PULM overbought or oversold?
At the July 15, 2026 close, PULM's RSI(14) was 57.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pulmatrix, Inc. reports $3.3M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$3.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -84.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $6.1M to $0.
With a beta above 1.5, PULM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PULM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.